Related references
Note: Only part of the references are listed.Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03
Xinan Sheng et al.
CLINICAL CANCER RESEARCH (2022)
SHR-1701, a Bifunctional Fusion Protein Targeting PD-L1 and TGFb, for Recurrent or Metastatic Cervical Cancer: A Clinical Expansion Cohort of a Phase I Study
Jifeng Feng et al.
CLINICAL CANCER RESEARCH (2022)
Recent progress in TGF-β inhibitors for cancer therapy
Cheng-Yi Huang et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
Novel therapies emerging in oncology to target the TGF-β pathway
Byung-Gyu Kim et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised multicentre, double-blind, phase 3 trial
Rui-Hua Xu et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)
Adverse event management during treatment with bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1: Treatment guidelines based on experience in clinical trials
J. Gulley et al.
ANNALS OF ONCOLOGY (2021)
A Potent Pan-TGFβ Neutralizing Monoclonal Antibody Elicits Cardiovascular Toxicity in Mice and Cynomolgus Monkeys
Mayur S. Mitra et al.
TOXICOLOGICAL SCIENCES (2020)
Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer
Yoon-Koo Kang et al.
CLINICAL CANCER RESEARCH (2020)
Assessment of Incidence Rate and Risk Factors for Keratoacanthoma Among Residents of Queensland, Australia
Magdalena Claeson et al.
JAMA DERMATOLOGY (2020)
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies
Julius Strauss et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Transforming Growth Factor-β Signaling in Immunity and Cancer
Eduard Batlle et al.
IMMUNITY (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E. W. Cohen et al.
LANCET (2019)
Mechanisms of Resistance to PD-1 and PD-L1 Blockade
Theodore S. Nowicki et al.
CANCER JOURNAL (2018)
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
Julius Strauss et al.
CLINICAL CANCER RESEARCH (2018)
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
Manish R. Patel et al.
LANCET ONCOLOGY (2018)
Contextual determinants of TGFβ action in development, immunity and cancer
Charles J. David et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2018)
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs et al.
JAMA ONCOLOGY (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Loss of TGF- signaling drives cSCC from skin stem cells - More evidence
Aidan M. Rose et al.
CELL CYCLE (2017)
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang et al.
LANCET (2017)
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
Padmanee Sharma et al.
LANCET ONCOLOGY (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Targeting TGF-β Signaling for Therapeutic Gain
Rosemary J. Akhurst
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2017)
Cutaneous squamous cell carcinoma: an epidemiological review
A. C. Green et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
TGF-β Tumor Suppression through a Lethal EMT
Charles J. David et al.
CELL (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Inactivation of TGFβ receptors in stem cells drives cutaneous squamous cell carcinoma
Patrizia Cammareri et al.
NATURE COMMUNICATIONS (2016)
Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor beta by the monoclonal antibody fresolimumab (GC1008)
Mario E. Lacouture et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
Hugo E. R. Ford et al.
LANCET ONCOLOGY (2014)
Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial
Shuichi Hironaka et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial
Jin Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Transforming growth factor-β signal transduction in angiogenesis and vascular disorders
P Bertolino et al.
CHEST (2005)
Share Paper
